Tusk Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 7

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $764M

Tusk Therapeutics General Information

Description

Developer of an innate immune system designed to harness the power of the immune system for the treatment of cancer. The company's system is developing novel immune modulating therapeutics based on an in-depth understanding of the innate immune system with a special focus on Natural Killer (NK) cell biology, enabling cancer patients to get full recovery.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Acquirer
Corporate Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road, Stevenage
  • Hertfordshire SG1 2FX
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tusk Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 27-Sep-2018 $764M 00000 Completed Pre-Clinical Trials
3. Grant 14-Nov-2017 00.000 Completed Pre-Clinical Trials
2. Early Stage VC 01-Jan-2014 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Tusk Therapeutics’s complete valuation and funding history, request access »

Tusk Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an innate immune system designed to harness the power of the immune system for the treatment of cancer. The
Biotechnology
Hertfordshire, United Kingdom
7 As of 2018
00000 0000-00-00
000000&0

000000

veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
0000 000000000
Vienna, Austria
00 As of 0000
000.00
000000 - 000 000.00

000000

t enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqui
0000 000000000
Cheshire, United Kingdom
00 As of 0000
000.00
0000 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tusk Therapeutics Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
APEIRON Biologics Venture Capital-Backed Vienna, Austria 00 000.00 000000 - 000 000.00
NeoPhore Venture Capital-Backed Cheshire, United Kingdom 00 000.00 00000000000 000.00
Iovance Biotherapeutics Corporation San Carlos, CA 000 00000 00000000 00000
TME Pharma Formerly VC-backed Berlin, Germany 00 00000 000000000 00000
Stemline Therapeutics Corporate Backed or Acquired New York, NY 000 00000 000000&0 00000
You’re viewing 5 of 38 competitors. Get the full list »

Tusk Therapeutics Patents

Tusk Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201804028-D0 Anti-cd25 antibody agents Inactive 13-Mar-2018
GB-201804029-D0 Anti-cd25 antibody agents Inactive 13-Mar-2018
GB-201804027-D0 Anti-cd25 antibody agents Inactive 13-Mar-2018
US-10738125-B2 Anti-cd25 antibody agents Active 13-Mar-2018 00000000000 00
US-10745485-B2 Anti-cd25 antibody agents Active 13-Mar-2018 C07K16/2866 00
To view Tusk Therapeutics’s complete patent history, request access »

Tusk Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Pascal Merchiers Ph.D Vice President of Research & Development
Dominic Smethurst Chief Medical Officer
You’re viewing 2 of 4 executive team members. Get the full list »

Tusk Therapeutics Board Members (5)

Name Representing Role Since
Eric Rowinsky Tusk Therapeutics Board Member 000 0000
You’re viewing 1 of 5 board members. Get the full list »

Tusk Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tusk Therapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Droia Ventures Venture Capital Minority 000 0000 000000 0
Innovate UK Accelerator/Incubator 000 0000 000000 0
Stevenage Bioscience Catalyst Accelerator/Incubator Minority 000 0000 000000 0
To view Tusk Therapeutics’s complete investors history, request access »

Tusk Therapeutics FAQs

  • When was Tusk Therapeutics founded?

    Tusk Therapeutics was founded in 2014.

  • Where is Tusk Therapeutics headquartered?

    Tusk Therapeutics is headquartered in Hertfordshire, United Kingdom.

  • What is the size of Tusk Therapeutics?

    Tusk Therapeutics has 7 total employees.

  • What industry is Tusk Therapeutics in?

    Tusk Therapeutics’s primary industry is Biotechnology.

  • Is Tusk Therapeutics a private or public company?

    Tusk Therapeutics is a Private company.

  • What is the current valuation of Tusk Therapeutics?

    The current valuation of Tusk Therapeutics is 00000.

  • What is Tusk Therapeutics’s current revenue?

    The current revenue for Tusk Therapeutics is 000000.

  • Who are Tusk Therapeutics’s investors?

    Droia Ventures, Innovate UK, and Stevenage Bioscience Catalyst have invested in Tusk Therapeutics.

  • Who are Tusk Therapeutics’s competitors?

    APEIRON Biologics, NeoPhore, Iovance Biotherapeutics, TME Pharma, and Stemline Therapeutics are some of the 38 competitors of Tusk Therapeutics.

  • When was Tusk Therapeutics acquired?

    Tusk Therapeutics was acquired on 27-Sep-2018.

  • Who acquired Tusk Therapeutics?

    Tusk Therapeutics was acquired by Roche.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »